Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
6,781 total articles
Lumexa Imaging has appointed Kyle Lynch as its new Chief Growth Officer to lead enterprise growth strategies including joint ventures, acquisitions, and new developments. Lynch will also enhance sales productivity and standardize performance metrics across the company's outpatient imaging centers. This move aims to capitalize on strong sector trend…
Sagimet Biosciences Inc. announced the appointment of Dr. Andreas Grauer as Chief Medical Officer, succeeding Dr. Eduardo Martins who retires and becomes an external scientific advisor. Dr. Grauer brings over 20 years of biopharmaceutical leadership experience and will lead the clinical development of Sagimet's FASN inhibitor drug candidates target…
Axalta Coating Systems has launched Zencore™, a new cabinet coating system designed to streamline manufacturing processes for high-volume operations in North America. Building on the technology of its premium Zenamel™ brand, Zencore™ reduces coating steps from three to two, improving throughput, cost efficiency, and reducing waste without compromis…
Cronos Group Inc. announced it will hold its 2026 first quarter earnings conference call on May 11, 2026, where senior management will discuss financial results and answer investor questions. The company, a global cannabis firm, continues to emphasize its strategy to build a leading international brand portfolio through R&D and innovation.
Sutro Biopharma presented encouraging preclinical data across several antibody-drug conjugate (ADC) programs, including STRO-004, STRO-006, and STRO-227, at the AACR 2026 meeting. STRO-004 demonstrated robust antitumor activity and favorable tolerability in solid tumor models, supporting advancement into clinical trials. Other pipeline candidates s…
Monopar Therapeutics announced Phase 3 trial results of ALXN1840 demonstrating greater neurologic improvement and reduced deterioration in Wilson disease patients with neurologic symptoms, compared to standard of care. The drug showed sustained benefits over multiple years and a favorable safety profile, supporting an FDA NDA submission planned for…
Immunocore Holdings plc announces that KIMMTRAK (tebentafusp-tebn) significantly improves five-year overall survival rates in first-line HLA-A*02:01 positive patients with metastatic uveal melanoma, doubling survival from 8% to 16%. The data, from the longest randomized Phase 3 trial in this disease and for any T cell engager in solid tumors, showc…
Xenon Pharmaceuticals reported highly positive Phase 3 X-TOLE2 study results demonstrating significant seizure frequency reductions with azetukalner in patients with focal onset seizures, alongside promising 48-month long-term efficacy and safety data from the ongoing open-label extension. The data highlights azetukalner's potential as a preferred …
Molecular Partners AG presented new preclinical data supporting its Switch-DARPin T cell engager MP0632 for solid tumors co-expressing MSLN and EpCAM, demonstrating tumor regression with a favorable safety profile. Additionally, the company showcased the molecular characteristics of MP0712, a Radio-DARPin candidate in an ongoing US Phase 1/2a trial…
Revolution Medicines, Inc. presented updated Phase 1 clinical data for zoldonrasib, an oral targeted inhibitor for KRAS G12D non-small cell lung cancer (NSCLC), showing favorable safety and encouraging efficacy results including a 52% objective response rate and prolonged progression-free survival. These results support further clinical development…
Pliant Therapeutics announced updated Phase 1 trial data demonstrating significant antitumor activity of PLN-101095, an oral integrin inhibitor, combined with pembrolizumab in patients with immune checkpoint inhibitor-refractory advanced solid tumors. Confirmed tumor responses showed an average maximum reduction of 89%, with median treatment durati…
argenx announced new Phase 3 data at AAN 2026 demonstrating that VYVGART, their biologic therapy, significantly improves symptoms in ocular myasthenia gravis, generalized myasthenia gravis regardless of antibody status, and early-stage CIDP patients. Additional studies showed positive results in adolescent patients and ongoing trials support expand…
B2Gold announced a fire at the crushing circuit of its Goose Mine on April 16, 2026. Emergency procedures were promptly executed, extinguishing the fire without injuries or operational halts. The fire was localized to the secondary crusher screen and feed belt. The company is investigating the cause and assessing any operational impact, with mining…
RedCloud Holdings plc disclosed that Nasdaq has notified the company it does not meet the minimum $1 bid price requirement. RedCloud has 180 days to regain compliance or risk delisting, with a possible additional 180-day extension. The company is focused on its commercial strategy and aims to restore compliance within the given period.
American Airlines Group Inc. issued a statement affirming no interest in merging with United Airlines, citing concerns over competition and consumer impact. The company expressed appreciation for the current administration's support of the aviation industry and emphasized its commitment to executing its strategic objectives independently.
Arbe Robotics Ltd., traded on Nasdaq under the ticker ARBE, announced that it received a notification from Nasdaq's Listing Qualifications Department indicating the company failed to meet the minimum bid price requirement of $1 per share for 30 consecutive business days. The company has 180 days to regain compliance or potentially face delisting, w…
Callan JMB Inc., a NASDAQ-listed integrative logistics company specializing in healthcare and emergency management supply chains, has been named in a lawsuit by Eddie Patent Holdings LLC. The company is reviewing the claims and believes them to be without merit. It emphasized that the pending litigation does not affect its operations or growth init…
Sonoco Products Company (NYSE: SON), a global leader in sustainable packaging, will report its first quarter 2026 financial results on April 21, 2026, followed by a conference call on April 22. The company highlights strong sustainability credentials and recognition in 2026 as one of the world's and America's most admired companies.
SEALSQ Corp, a Nasdaq-listed company specializing in post-quantum technology including semiconductors and PKI solutions, announced its 2026 Annual General Meeting to be held on May 7, 2026 in Miami, Florida. The meeting will cover re-election of board members, recent financial and operational performance, and the company's strategic outlook. Shareh…
Theriva Biologics announced new tumor response, biomarker, and subgroup analyses from its VIRAGE Phase 2b clinical trial evaluating VCN-01 combined with gemcitabine/nab-paclitaxel in metastatic pancreatic cancer patients. The data, to be presented at AACR 2026, reinforce VCN-01's immune-mediated mode of action and demonstrate improved outcomes, inc…
Value Line, Inc. announced a 7.7% increase in its quarterly dividend to $0.35 per share ($1.40 annualized), reflecting its 12th consecutive annual dividend increase. The dividend is payable on May 12, 2026, to shareholders of record as of April 27, 2026. The company provides a broad range of investment research products and services, including equi…
Adagene Inc. presented new clinical data at AACR 2026 demonstrating that their masked anti-CTLA-4 therapy muzastotug, when combined with immunotherapies like atezolizumab and bevacizumab or pembrolizumab and fruquintinib, shows significantly improved overall response rates and manageable safety profiles in advanced hepatocellular carcinoma and micr…
NEXGEL, Inc. has rescheduled its shareholder update conference call from April 23rd to April 21st, 2026 at 4:30 P.M. ET to discuss the Celularity transaction. The company produces healthcare, beauty, and OTC hydrogel products and maintains strategic manufacturing partnerships.
Evaxion A/S announced promising phase 2 trial data for its personalized cancer vaccine EVX-01, designed with its AI-Immunology™ platform, showing an 86% success rate in vaccine targets eliciting tumor-specific immune responses. The data, presented at the AACR Annual Meeting, reinforce the platform's capability to select relevant vaccine targets and…
Immatics announced that a pediatric patient with advanced metastatic nephroblastoma achieved deep and durable remission following an individual experimental treatment using their PRAME-directed T-cell receptor (TCR) therapy. The treatment led to marked regression of metastases in multiple organs and ongoing remission at 6 months, highlighting the p…
